Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indanidine SCHEMBL10952387 | 0.99 | ADRA2A (0.51) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| Hydrochloric Acid SCHEMBL11039548 | 0.81 | ADRA2A (0.51) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11047780 | 0.78 | ADRA2A (0.46) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11186400 | 0.77 | ADRA2A (0.54) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11186021 | 0.74 | ADRA2A (0.52) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL10956413 | 0.74 | ADRA2A (0.52) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11061959 | 0.73 | ADRA2A (0.47) | ADRA2AADRA1AADRA2CADRA1DADRA1B | |
| SCHEMBL9721191 | 0.73 | ADRA2A (0.48) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL30357746 | 0.73 | ADRA2A (0.62) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL1741683 | 0.73 | ADRA2A (0.62) | ADRA2AADRA1AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | claimed |
| US-20230310420-A1 | METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION | UNIV MIDWESTERN (US) | 2023-10-05 | — | — | US | claimed |
| US-20230165836-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER | Université Catholique de Louvain (BE) | 2023-06-01 | — | — | US | claimed |
| US-20230149360-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS | Université Catholique de Louvain (BE) | 2023-05-18 | — | — | US | claimed |
| EP-4138803-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER | Université catholique de Louvain (BE) | 2023-03-01 | — | — | EP | claimed |
| EP-4138802-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS | Université catholique de Louvain (BE) | 2023-03-01 | — | — | EP | claimed |
| US-20220218630-A1 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS | JENIVISION INC. | 2022-07-14 | — | — | US | claimed |
| EP-3979996-A1 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS | Jenivision Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| WO-2021214175-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS FOR THE PREVENTION AND/OR THE TREATMENT OF SPLEEN DISORDERS | Université Catholique de Louvain (BE) | 2021-10-28 | — | — | WO | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1864671-A1 | THE USE OF HYDROCHLORIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPERTENSION | Liu, Zhiren (CN) | 2007-12-12 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0719139-A1 | USE OF CENTRALLY ACTIVE ALPHAAGONISTS FOR INHIBING POSTRAUMATIC METABOLIC STRESS | Dr. Karl Thomae GmbH (DE) | 1996-07-03 | — | — | EP | claimed |
| WO-1995003798-A2 | USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM | BOEHRINGER INGELHEIM INT (DE) | 1995-02-09 | — | — | WO | claimed |
| EP-0170193-B1 | FEEDSTUFF ADDITIVE FOR THE GROWTH PROMOTING OF AGRICULTURAL USEFUL ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
| US-4526898-A | Hypotensive agents | SIEGFRIED AKTIENGESSELSCHAFT (CH) | 1985-07-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310420-A1 | METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION | ADRA2A, ADRA2C, ADRB2 | ADRA2A 1/4885ADRA1A 9/4885ADRA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.